Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2013

View Archived Issues

Novel small molecules useful as imaging tools in patients with cancer

Uncovering the antioxidative potential of paroxetine in hyperglycemic conditions

New CSF biomarker panel assay developed for the diagnosis of AD

Blood-based gene signature model for early detection of PD

Kowa and Daiichi Sankyo to end marketing partnership in Japan

AstraZeneca reports topline results from phase III fostamatinib study

Idenix Pharmaceuticals divulges novel agents for HCV infection

Canadian approval for Hologic's HPV assays

Emergent BioSolutions expands phase Ib study of TRU-016 with rituximab in CLL

ELOVL6 inhibitors suitable for treating insulin resistance

AC-708 described as CSF-1R inhibitor

Sanofi designs novel PKC-beta inhibitors

FDA approves Prolensa for postoperative inflammation and ocular pain

Ibrutinib receives third FDA breakthrough therapy designation

Roche and Isis Pharmaceuticals partner for Huntington's disease

Government of Japan, Gates Foundation and consortium of pharmaceutical companies launch partnership

Dainippon Sumitomo and Chugai agree to terminate joint development of anticancer vaccine candidates

Theratechnologies and Ferrer end tesamorelin agreement

Spectrum Pharmaceuticals commences phase II study of treatment for chemotherapy-induced neutropenia

Roche presents new aldosterone synthase inhibitors

DiaMedica cleared to conduct trial of lead diabetes treatment candidate

Anacor and Gates Foundation sign research agreement for neglected disease research

FDA approves Diclegis for morning sickness

Proximagen prepares new SSAO inhibitors

Glenmark Pharmaceuticals patents new MPGES-1 inhibitors

Crown Bioscience and Horizon Discovery sign new collaboration agreement